Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Microstent offers new hope for stubborn glaucoma

NCT ID NCT03267134

Disease control Sponsor: Ivantis, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a small device called the Hydrus Microstent in 217 adults with open-angle glaucoma that was not well controlled with other treatments. The goal was to see if the implant could safely lower eye pressure. After 12 months, many patients had a significant drop in eye pressure while using the same or fewer eye drops.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

217 people

The number who actually took part.

Started

Aug 2017

Finished

Dec 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Open-angle glaucoma with optic nerve pathology; * BCVA of 20/80 or better in study eye; * Refractory glaucoma; * Other protocol-specified inclusion criteria may apply. Exclusion Criteria: * Secondary glaucoma other than pseudoexfoliative and pigmentary glaucoma; * Acute angle closure, chronic angle closure, or congenial, malignant, or developmental glaucoma; * Pre-perimetric glaucoma; * Ocular hypertension * Shallow or flat anterior chamber; * Other protocol-specified exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Open angle glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Open angle glaucoma

Contacts and locations

Locations

  • Asian Eye Institute

    Makati City, 1200, Philippines

  • Center for Sight

    Venice, Florida, 34283, United States

  • Clínica Oftalmológica

    Barranquilla, 080020, Colombia

  • El Paso Eye Surgeons

    El Paso, Texas, 79902, United States

  • Eye Center of Northern Colorado

    Fort Collins, Colorado, 80528, United States

  • Glaucoma Associates of Texas

    Dallas, Texas, 75231, United States

  • Hospital Universitario Miguel Servet

    Zaragoza, 50009, Spain

  • Louisiana Eye and Laser Center

    Alexandria, Louisiana, 71303, United States

  • Manchester Royal Eye Hospital

    Manchester, M13 9WL, United Kingdom

  • Ocala Eye

    Ocala, Florida, 34474, United States

  • Ophthalmology Associates

    Fort Worth, Texas, 76102, United States

  • R and R Research, LLC

    San Antonio, Texas, 78229, United States

  • Sacramento Eye Consultants

    Sacramento, California, 95815, United States

  • Scott & Christie and Associates

    Cranberry Township, Pennsylvania, 16066, United States

  • Stiles Eyecare

    Overland Park, Kansas, 66213, United States

  • Texan Eye

    Austin, Texas, 78731, United States

  • The Eye Centers of Racine and Kenosha

    Kenosha, Wisconsin, 53142, United States

  • Vale-Asche Russell Clinical Research Center

    Houston, Texas, 77030, United States

  • Vold Vision

    Fayetteville, Arkansas, 72704, United States

  • Washington University in St. Louis Ophthalmology

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.